JNJ Stock May Be 14% Overvalued Despite Recent Momentum

Johnson & Johnson (JNJ) stock is gaining momentum following the FDA clearance of its MONARCH QUEST 3 bronchoscopy system, along with growth in its Innovative Medicine segment. However, despite this positive trend, some analysts believe the company's stock may be overvalued.

A recent analysis by Simply Wall St suggests that Johnson & Johnson could be around 14% overvalued at its current share price of $262.37. This estimate is based on a fair value calculation of $230.82.

The valuation narrative leans on rising revenue, firmer margins, and a richer profit multiple over time. However, this narrative can crack if regulators push back on AI-generated evidence or if faster-moving rivals capture key oncology and MedTech markets.

Interestingly, the company's discounted cash flow (DCF) model presents a different perspective, indicating that the stock is trading around 28% below an estimated future cash flow value of $364.27. This discrepancy raises questions about which set of assumptions appears more realistic for Johnson & Johnson over time.